文献速递类风湿关节炎脊柱关节炎其他结缔组织病

免疫介导炎症性疾病女性妊娠期用药与妊娠结局:英国匹配队列研究

Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

基于英国临床实践研究数据链的匹配队列研究,评估类风湿关节炎、银屑病关节炎、银屑病、脊柱关节炎和炎症性肠病女性妊娠期用药模式及妊娠结局。结果显示银屑病和炎症性肠病女性自然流产风险轻度增加,炎症性肠病后代总体主要先天性畸形风险边缘性增加,但使用硫唑嘌呤、美沙拉秦和柳氮磺吡啶未见自然流产风险增加。

要点

  • 类风湿关节炎、银屑病关节炎和脊柱关节炎女性自然流产风险未增加。
  • 银屑病和炎症性肠病女性自然流产风险轻度增加。
  • 炎症性肠病后代主要先天性畸形风险边缘性增加,需谨慎解读。

核心结论

  • 类风湿关节炎、银屑病关节炎或脊柱关节炎女性自然流产风险未增加,银屑病或炎症性肠病女性风险轻度增加。
  • 炎症性肠病女性后代总体主要先天性畸形风险边缘性增加,可能受残余混杂影响。

研究设计与样本

  • 基于英国临床实践研究数据链2000年1月1日至2020年6月31日的匹配队列研究。
  • 纳入类风湿关节炎、银屑病关节炎、银屑病、脊柱关节炎和炎症性肠病女性妊娠,并与无这些诊断的女性妊娠匹配。

主要发现

  • 自然流产风险调整风险比从银屑病关节炎的1.01(95%CI 0.79, 1.28)至炎症性肠病的1.18(95%CI 1.07, 1.30)。
  • 主要先天性畸形总体风险未显著增加,仅炎症性肠病在敏感性分析中边缘性显著(调整比值比1.31,95%CI 1.00, 1.71)。
  • 使用硫唑嘌呤、美沙拉秦和柳氮磺吡啶的女性未观察到自然流产风险增加。

临床怎么用

  • 对银屑病或炎症性肠病妊娠女性应关注自然流产风险,炎症性肠病后代需谨慎评估主要先天性畸形风险。
  • 妊娠期使用硫唑嘌呤、美沙拉秦或柳氮磺吡啶未见自然流产风险增加,可作为用药参考。

局限性

  • 炎症性肠病主要先天性畸形风险边缘性增加可能受残余混杂影响,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immune mediated inflammatory diseases (IMID) affect women of childbearing age, yet there is a lack of evidence about the risk of adverse pregnancy outcomes and the interaction with medication. This study aims to characterize prescribing patterns and pregnancy outcomes in women with an IMID diagnosis. METHODS: Pregnancies to women with rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), spondyloarthritis (SpA) and inflammatory bowel disease (IBD) were identified within the Clinical Practice Research Datalink, between 1 January 2000 and 31 June 2020, and matched to pregnancies in women with no such diagnosis. Drug prescribing patterns were described during and surrounding pregnancy. The risk of spontaneous pregnancy loss and major congenital malformations (MCMs) were evaluated compared with women without an IMID. Exposure to commonly prescribed disease-modifying anti-rheumatic drugs was evaluated. RESULTS: The risk of a spontaneous pregnancy loss ranged from adjusted hazard ratio (HRadj) 1.01 (95% CI: 0.79, 1.28) for PsA to HRadj 1.18 (95% CI: 1.07, 1.30) for IBD when compared with women without these conditions. No significant increases in the overall risk of MCMs were observed, with the exception of IBD where it reached borderline significance based on sensitivity analyses [adjusted odds ratio 1.31 (95% CI: 1.00, 1.71)]. No evidence of an increased risk of spontaneous loss was observed in women taking azathioprine, mesalazine and sulfasalazine. CONCLUSION: We found no increased risk of spontaneous loss in women with RA, PsA or SpA but a small increase in women with psoriasis or IBD. There was a borderline increased risk of all MCMs in offspring of women with IBD, which should be interpreted cautiously because of potential residual confounding.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Charlton R, Tillett W, McHugh N, et al. Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study. Rheumatology (Oxford). 2026. PMID: 42565551. doi:10.1093/rheumatology/keag395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。